Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 13/20 | 0.61 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25884637 | 0.82 | HCAR3 (0.65) | HCAR3HCAR2GRM5GABRA5 | |
| SCHEMBL186420 | 0.77 | HCAR3 (1.00) | HCAR3HCAR2 | |
| SCHEMBL5429479 | 0.75 | HDAC1 (0.50) | GABRA5ALDH1A1 | |
| SCHEMBL11546416 | 0.75 | HCAR3 (0.73) | HCAR3HCAR2ADRA2AADRA2BADRA2C | |
| SCHEMBL692654 | 0.74 | HCAR3 (0.71) | HCAR3HCAR2ADRA2AADRA2BADRA2C | |
| SCHEMBL23341627 | 0.74 | GABRA5 (0.42) | HCAR3HCAR2GABRA5ALDH1A1 | |
| SCHEMBL31661260 | 0.73 | HCAR3 (0.69) | HCAR3HCAR2ADRA2AADRA2BADRA2C | |
| SCHEMBL24101021 | 0.72 | HCAR3 (0.67) | HCAR3HCAR2ALDH1A1LMNA | |
| SCHEMBL25905785 | 0.71 | ADRA2A (0.40) | HCAR3ADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL25905786 | 0.71 | HCAR3 (0.61) | HCAR3HCAR2GRM5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11566007-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566007-B2 | Ras inhibitors | KRAS, NRAS, HRAS | HCAR3 4500/4885HCAR2 4728/4885GRM5 4633/4885 |
| US-20230234929-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HCAR3 4500/4885HCAR2 4728/4885GRM5 4633/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | HCAR3 4500/4885HCAR2 4728/4885GRM5 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.